Pexidartinib
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Tenosynovial Giant Cell Tumor
Conditions
Tenosynovial Giant Cell Tumor
Trial Timeline
Oct 20, 2020 → Jul 7, 2023
NCT ID
NCT04526704About Pexidartinib
Pexidartinib is a approved stage product being developed by Daiichi Sankyo for Tenosynovial Giant Cell Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT04526704. Target conditions include Tenosynovial Giant Cell Tumor.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04703322 | Phase 2 | Active |
| NCT04526704 | Approved | Completed |
| NCT04488822 | Phase 3 | Active |
| NCT04223635 | Phase 1 | Completed |
| NCT02734433 | Phase 1 | Completed |
Competing Products
2 competing products in Tenosynovial Giant Cell Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pexidartinib | Daiichi Sankyo | Phase 2 | 52 |
| Pexidartinib | Daiichi Sankyo | Phase 3 | 77 |